Abstract

Aims

Niacin has potentially favourable effects on lipids, but its effect on cardiovascular outcomes is uncertain. HPS2-THRIVE is a large randomized trial assessing the effects of extended release (ER) niacin in patients at high risk of vascular events.

Methods and results

Prior to randomization, 42 424 patients with occlusive arterial disease were given simvastatin 40 mg plus, if required, ezetimibe 10 mg daily to standardize their low-density lipoprotein (LDL)-lowering therapy. The ability to remain compliant with ER niacin 2 g plus laropiprant 40 mg daily (ERN/LRPT) for ∼1 month was then assessed in 38 369 patients and about one-third were excluded (mainly due to niacin side effects). A total of 25 673 patients were randomized between ERN/LRPT daily vs. placebo and were followed for a median of 3.9 years. By the end of the study, 25% of participants allocated ERN/LRPT vs. 17% allocated placebo had stopped their study treatment. The most common medical reasons for stopping ERN/LRPT were related to skin, gastrointestinal, diabetes, and musculoskeletal side effects. When added to statin-based LDL-lowering therapy, allocation to ERN/LRPT increased the risk of definite myopathy [75 (0.16%/year) vs. 17 (0.04%/year): risk ratio 4.4; 95% CI 2.6–7.5; P < 0.0001]; 7 vs. 5 were rhabdomyolysis. Any myopathy (definite or incipient) was more common among participants in China [138 (0.66%/year) vs. 27 (0.13%/year)] than among those in Europe [17 (0.07%/year) vs. 11 (0.04%/year)]. Consecutive alanine transaminase >3× upper limit of normal, in the absence of muscle damage, was seen in 48 (0.10%/year) ERN/LRPT vs. 30 (0.06%/year) placebo allocated participants.

Conclusion

The risk of myopathy was increased by adding ERN/LRPT to simvastatin 40 mg daily (with or without ezetimibe), particularly in Chinese patients whose myopathy rates on simvastatin were higher. Despite the side effects of ERN/LRPT, among individuals who were able to tolerate it for ∼1 month, three-quarters continued to take it for ∼4 years.

See page 1254 for the editorial comment on this article (doi:10.1093/eurheartj/eht064)

Introduction

Cardiovascular risk remains elevated in some high-risk patients even after lowering low-density lipoprotein cholesterol (LDL-C) with statins, controlling blood pressure and diabetes, and stopping smoking.1,2 Targeting other aspects of lipid metabolism, such as high-density lipoprotein cholesterol (HDL-C), triglycerides, and lipoprotein (a) [Lp(a)], as well as lowering LDL-C further, offers the prospect of additional cardiovascular risk reduction.3,4

Niacin has potentially beneficial effects on multiple lipid fractions

Niacin is an old drug whose lipid modification properties at high doses have been recognized for many years.5 In patients already receiving a statin, extended release (ER) niacin 2 g daily is reported to increase HDL-C by ∼20% and apolipoprotein A1 (apoA1) by ∼7%, as well as reducing LDL-C, apolipoprotein B (apoB), and Lp(a) levels by ∼20% and triglycerides by ∼25%.6 Previous observational studies have demonstrated a strong positive association of cardiovascular disease risk with LDL-C and a strong inverse association with HDL-C. Randomized trials of statin therapy indicate that the LDL-C association is causal,1 but it remains uncertain whether the association with HDL-C is causal. There is also evidence for a causal association between Lp(a) and CHD, with lower Lp(a) associated with lower CHD risk.7 Niacin does, therefore, have multiple effects on lipid metabolism which might be beneficial. In addition, niacin can reduce blood pressure, but it also has potentially adverse effects on glucose metabolism.8,9

Uncertainty remains about clinical benefits of niacin in the modern era

The first large randomized trial to have assessed the effects of niacin on clinical outcomes was the coronary drug project (CDP) in 8341 post-myocardial infarction (MI) men. Allocation to niacin 3 g daily reduced total cholesterol by ∼0.7 mmol/L and this was associated with a significant 19% (95% CI 4–31%) reduction in the incidence of non-fatal MI or coronary death.10 However, the CDP was conducted more than 30 years ago, before statins and other effective cardioprotective treatments were available, making its applicability in the present day unclear. More recently, the AIM-HIGH study in 3414 high-risk patients of adding ER niacin 1.5–2.0 g daily to statin therapy was stopped prematurely because of perceived lack of benefit (hazard ratio 1.02; 95% CI 0.87–1.21),11 but the observed mean lipid differences were small (0.12 mmol/L lower LDL-C and 0.13 mmol/L higher HDL-C in the niacin group). Such changes in lipids might be expected to reduce CHD risk by at most 10%, but AIM-HIGH was too small to detect such an effect reliably.

Niacin has a number of side effects which limit its use in some people. In particular, it causes an unpleasant cutaneous vasodilatation (‘flushing’) in almost all patients who take therapeutic doses of immediate-release niacin and up to two-thirds of those taking ER niacin.12 Episodes of flushing with niacin (but not other adverse effects) are principally mediated by prostaglandin D2 release in the skin.13 Laropiprant is a specific antagonist of DP1, the prostaglandin D2 receptor, which reduces this flushing and has been shown to improve niacin tolerability.14 The HPS2-THRIVE trial is assessing the effects on cardiovascular and other major outcomes of adding the combination of ER niacin 2 g with laropiprant 40 mg (ERN/LRPT) daily to effective statin treatment in 25 673 patients with occlusive arterial disease. The present report describes the trial design, patient characteristics, and reasons for stopping study treatment, along with the information on myopathy and liver-related events that were pre-specified to be reported prior to the main clinical outcomes (see Supplementary material online).

Methods

Objectives

The primary aim of HPS2-THRIVE is to assess the effect of ER niacin 2 g plus laropiprant 40 mg daily vs. matching placebo on the time to first ‘major vascular event’ (MVE: a composite of non-fatal MI, coronary death, stroke, or arterial revascularization) among high-risk patients with pre-existing occlusive arterial disease who are receiving effective statin-based LDL-lowering therapy. Further details about secondary and tertiary assessments are available in the Data Analysis Plans (see Supplementary material online).

For the purposes of the present report, reasons for stopping study treatment were to be compared overall and also grouped by body system or affected organ. In addition, liver and muscle safety outcomes were to include two or more consecutive elevations of alanine transaminase (ALT) >3× upper limit of normal (ULN); presumed study-drug-related hepatitis; definite myopathy; rhabdomyolysis; and incipient myopathy (which indicated a high risk of, and shared a genetic predisposition with, subsequent myopathy in a previous trial15) (see Data Analysis Plans for definitions).

Eligibility

The inclusion and exclusion criteria (Figure 1) were designed to allow the recruitment of a wide range of participants at high risk of vascular events while excluding those for whom the safety of simvastatin or ERN/LRPT might be a concern, or for whom more potent LDL-lowering or niacin treatment was considered to be indicated. There were no lipid inclusion criteria as HPS2-THRIVE aims to examine the effects on MVEs among participants with various lipid profiles (e.g. higher or lower LDL-C and HDL-C).

Figure 1

Inclusion and exclusion criteria.

Figure 1

Inclusion and exclusion criteria.

Invitation and screening

Potentially eligible patients were identified from hospital or clinic records or by local advertisement and invited to attend a clinic where specially trained study staff completed an electronic study questionnaire about their past medical history, current treatments and other factors relevant to eligibility and vascular risk. Blood pressure was measured and a blood sample taken (participants were asked to fast before attending although it was not mandated, and time since last meal was recorded) with an immediate measurement of ALT, creatine kinase (CK) and creatinine using a Reflotron Plus (Roche) dry chemistry analyser (which was found to produce values in close agreement with those obtained by the central laboratory). Patients who appeared eligible were provided with a written description of the study and invited to participate (after, if they wished, discussing it with their family or other doctors). All who agreed to participate provided their written consent and stopped any current statin therapy.

Run-in period and randomization

Prior to randomization, participants had their LDL-lowering therapy standardized in order to minimize post-randomization treatment changes. Each participant received simvastatin 40 mg daily or, if not sufficient to achieve a total cholesterol <3.5 mmol/L when measured after 4 weeks, simvastatin 40 mg plus ezetimibe 10 mg daily (in each case as a single open-label tablet). In all cases, the LDL-lowering therapy given at the initial study screening visit was at least as intensive as the participant's current treatment, and those who were already receiving simvastatin 40 mg daily with total cholesterol <3.5 mmol/L or simvastatin/ezetimibe 40/10 mg daily entered the active ERN/LRPT phase of run-in directly from screening (see below). The local clinical investigators were provided with the dry chemistry total cholesterol value of each participant when taking the LDL-lowering treatment that it was proposed to be used in the trial, and asked to withdraw their patient if they did not wish them to be randomized (e.g. because the patient's lipids were not considered to be adequately controlled).

In the second part of the pre-randomization run-in phase, all participants received the addition of ER niacin 1 g plus laropiprant 20 mg daily for 4 weeks followed by ER niacin 2 g plus laropiprant 40 mg daily taken orally at night for a further 3–6 weeks. The aim of the active run-in phase was to reduce the rate of post-randomization discontinuation of study treatment and to produce a consequent improvement in statistical sensitivity for assessing any beneficial effects of prolonged treatment with ER niacin.16 It should be noted, however, that this means that the post-randomization rates of side effects and reasons for stopping study treatment relate to patients able to tolerate ∼1 month of ERN/LRPT.

Participants were randomized provided they reported taking at least 90% of their scheduled ERN/LRPT and LDL-lowering study tablets during the run-in phase and remained willing and eligible. At the randomization visit, height, weight, and waist circumference were measured, degree of flushing assessed, and history of heart failure recorded. Randomization using a minimization algorithm17 (involving age, gender, prior disease, smoking, total cholesterol, blood pressure, ethnic origin, prior statin use, diabetes, and LDL-lowering treatment) was provided by the study clinic computer which was synchronized frequently with the study database at the coordinating centre in the Clinical Trial Service Unit, Oxford via secure internet connection.

Post-randomization follow-up and safety monitoring

Study follow-up visits were conducted at 3 and 6 months following randomization and then 6 monthly. Study clinic staff systematically sought information on all serious adverse events, any non-serious adverse events considered by participants to be related to, or that resulted in stopping, study treatment, on muscle pain or weakness, and on symptoms suggestive of hepatitis (nausea, vomiting, or jaundice). The coordinating centre sought further details from the participant's medical records about all reports that might relate to MVEs or safety outcomes, and from national registries (where available) about cancers and the certified causes of any deaths. All such information was reviewed by coordinating centre clinicians (blind to treatment allocation) and events adjudicated according to pre-specified criteria.

Compliance with study treatment was assessed and, if relevant, a reason for discontinuation was recorded. Participants prescribed contra-indicated drugs (non-study niacin or fibrates) had their randomized treatment (ERN/LRPT or placebo) stopped. Those who were prescribed a non-study statin or drugs known to increase the risk of statin-induced myopathy had their study LDL-lowering treatment stopped. At each follow-up visit, dry chemistry analysers were used to measure ALT and, if ALT >1.5× ULN or muscle symptoms were reported, also CK. Externally measured CK and ALT results associated with events of interest were also recorded in the study database and included in these analyses. Consecutive elevations of ALT >3× ULN, any ALT >10× ULN or ALT >3× ULN with bilirubin ≥2× ULN without clear alternative causes led to permanent discontinuation of randomized treatment. Persistent CK >10× ULN without muscle symptoms or >5× ULN with muscle symptoms led to discontinuation of both study treatments. Other elevations of ALT or CK were managed (including recall visits to reassess symptoms and measure ALT and CK levels) after review by coordinating centre clinicians in collaboration with doctors at the local site, with the aim of minimizing myopathy or liver injury risk.

Central laboratory analyses and storage

Blood and urine samples were collected at the end of the LDL-C standardization phase (while participants were taking their allocated LDL-lowering therapy) and sent to a central laboratory for analysis of a lipid profile, creatinine, glycated haemoglobin (HbA1c), full blood count (in the UK only) and urinary albumin:creatinine ratio, and for long-term storage in liquid nitrogen of plasma, urine, and buffy coat aliquots (for possible future analyses). Blood samples were also taken for central laboratory analysis at the randomization visit and 3 month post-randomization visit (UK only), and, along with a urine sample, in a random 5% sample of participants each year, in all participants at a median follow-up of 1 year for their region and at the final follow-up visit. Details of assay methodology are given in the appendix (see Supplementary material online).

Statistical methods

Pre-specified assessments involve comparisons among all randomized participants in their originally allocated treatment group, irrespective of compliance [i.e. intention-to-treat (ITT)] up to the point of censoring for these analyses. ITT comparisons were made to assess reliably the modest differences between active treatment and placebo in various common outcomes (rather than to detect large effects on rare outcomes which might be assessed by non-randomized comparisons). Numbers of participants and, where appropriate, proportions or annual rates based on person years in the study are presented. Unadjusted Cox proportional hazards models were used to estimate risk ratios. For interpretation of these safety analyses, allowance has been made for multiple hypothesis testing by taking into account the nature of the event and evidence from other studies (see Supplementary material online). Analyses were conducted using SAS version 9.1 (SAS Institute, Cary, NC, USA).

Results

After relevant ethics and regulatory approvals had been obtained, study sites were established in China (72 hospitals or clinics), UK (89), Denmark (22), Finland (10), Norway (21), and Sweden (31). A total of 51 698 patients attended the study screening clinics: 16 861 in China, 24 396 in the UK, and 10 441 in Scandinavia; and 97, 66, and 95%, respectively, entered the run-in (Figure 2).

Figure 2

Trial profile: Flow of participants through the trial. Participants receiving simvastatin 40 mg (with total cholesterol <3.5 mmol/L) or ezetimibe/simvastatin 10/40 mg prior to screening entered the active ER niacin/laropiprant phase of the run-in immediately after the screening visit. *Participants may have more than one reason for being excluded.

Figure 2

Trial profile: Flow of participants through the trial. Participants receiving simvastatin 40 mg (with total cholesterol <3.5 mmol/L) or ezetimibe/simvastatin 10/40 mg prior to screening entered the active ER niacin/laropiprant phase of the run-in immediately after the screening visit. *Participants may have more than one reason for being excluded.

Pre-randomization run-in

Overall, 4055 (11.2%) of the 36 059 individuals who entered the LDL-lowering standardization phase withdrew prior to the ERN/LRPT phase (Table 1). Serious adverse reactions were given as reasons for withdrawal by six patients: five myopathy and one hepatitis. Of the 38 369 individuals who entered the active ERN/LRPT phase, 12 696 (33.1%) withdrew prior to randomization. Overall, medical reasons were four times as commonly cited as a reason for withdrawing during the active ERN/LRPT phase (average duration: 7.4 weeks) than during the LDL-lowering phase (4.6 weeks). As expected with niacin, the most common reasons were skin reactions (mainly pruritus, rashes, and flushing), and gastrointestinal symptoms (mainly nausea, and diarrhoea). Serious adverse reactions were given as reasons for withdrawal by 69 patients: 29 myopathy; 10 (pre-)syncopal; 8 skin-related; 6 gastrointestinal; 6 allergic; 3 diabetes related; 3 biochemical; 2 cardiac; and 2 other events. Non-medical reasons were also more commonly reported in the active ERN/LRPT phase, with an excess of difficulty swallowing tablets.

Table 1

Reasons for withdrawal from pre-randomization run-in

 LDL-lowering therapy alone LDL-lowering therapy plus active ERN/LRPT 
Number entering phase 36 059 38 369 
Mean duration of phase (weeks) 4.6 7.4 
Medical reasons   
 Skin   
  Pruritis 80 (0.2%) 2536 (6.6%) 
  Rash 65 (0.2%) 1416 (3.7%) 
  Flushing 20 (<0.1%) 646 (1.7%) 
  Other skin 13 (<0.1%) 192 (0.5%) 
  Any skin reason 170 (0.5%) 4326 (11.3%) 
 Gastrointestinal (GI)   
  Any upper GIa 208 (0.6%) 1108 (2.9%) 
  Any lower GI 170 (0.5%) 883 (2.3%) 
  Other GI 98 (0.3%) 278 (0.7%) 
  Any gastrointestinal reason 454 (1.3%) 2117 (5.5%) 
 Hepatobiliary   
  Abnormal alanine transaminaseb 223 (0.6%) 472 (1.2%) 
  Other hepatobiliary 2 (<0.1%) 9 (<0.1%) 
  Any hepatobiliary reason 225 (0.6%) 481 (1.3%) 
 Musculoskeletal   
  Muscle symptomsa 268 (0.7%) 498 (1.3%) 
  Rheumatological 65 (0.2%) 196 (0.5%) 
  Gout 5 (<0.1%) 60 (0.2%) 
  Abnormal creatine kinase 12 (<0.1%) 33 (<0.1%) 
  Other musculoskeletal 397 (1.1%) 381 (1.0%) 
  Any musculoskeletal reason 704 (2.0%) 1096 (2.9%) 
 Diabetes   
  New-onset diabetes mellitus 0 (0.0%) 3 (<0.1%) 
  Major diabetes complication 0 (0.0%) 5 (<0.1%) 
  Other diabetes-related reason 26 (<0.1%) 656 (1.7%) 
  Any diabetes-related reason 26 (<0.1%) 664 (1.7%) 
 Other medical   
  Pre-syncope/syncope 55 (0.2%) 261 (0.7%) 
  Palpitations 36 (<0.1%) 123 (0.3%) 
  Other cardiovascular 186 (0.5%) 436 (1.1%) 
  Respiratory 25 (<0.1%) 118 (0.3%) 
  Cancer 12 (<0.1%) 45 (0.1%) 
  Other 380 (1.1%) 1277 (3.3%) 
  Contraindicated medication 25 (<0.1%) 49 (0.1%) 
  Medical advice 90 (0.2%) 157 (0.4%) 
  Planned revascularization 8 (<0.1%) 45 (0.1%) 
  Any other medical reason 802 (2.2%) 2354 (6.1%) 
Any medical reason 2211 (6.1%) 9798 (25.5%) 
Non-medical reasons   
  Patient wishes/did not attend 1502 (4.2%) 2403 (6.3%) 
  Difficulty swallowing tablets 68 (0.2%) 746 (1.9%) 
  Other 639 (1.8%) 1317 (3.4%) 
Any non-medical reason 1988 (5.5%) 3804 (9.9%) 
Any reason 4055 (11.2%) 12 696 (33.1%) 
 LDL-lowering therapy alone LDL-lowering therapy plus active ERN/LRPT 
Number entering phase 36 059 38 369 
Mean duration of phase (weeks) 4.6 7.4 
Medical reasons   
 Skin   
  Pruritis 80 (0.2%) 2536 (6.6%) 
  Rash 65 (0.2%) 1416 (3.7%) 
  Flushing 20 (<0.1%) 646 (1.7%) 
  Other skin 13 (<0.1%) 192 (0.5%) 
  Any skin reason 170 (0.5%) 4326 (11.3%) 
 Gastrointestinal (GI)   
  Any upper GIa 208 (0.6%) 1108 (2.9%) 
  Any lower GI 170 (0.5%) 883 (2.3%) 
  Other GI 98 (0.3%) 278 (0.7%) 
  Any gastrointestinal reason 454 (1.3%) 2117 (5.5%) 
 Hepatobiliary   
  Abnormal alanine transaminaseb 223 (0.6%) 472 (1.2%) 
  Other hepatobiliary 2 (<0.1%) 9 (<0.1%) 
  Any hepatobiliary reason 225 (0.6%) 481 (1.3%) 
 Musculoskeletal   
  Muscle symptomsa 268 (0.7%) 498 (1.3%) 
  Rheumatological 65 (0.2%) 196 (0.5%) 
  Gout 5 (<0.1%) 60 (0.2%) 
  Abnormal creatine kinase 12 (<0.1%) 33 (<0.1%) 
  Other musculoskeletal 397 (1.1%) 381 (1.0%) 
  Any musculoskeletal reason 704 (2.0%) 1096 (2.9%) 
 Diabetes   
  New-onset diabetes mellitus 0 (0.0%) 3 (<0.1%) 
  Major diabetes complication 0 (0.0%) 5 (<0.1%) 
  Other diabetes-related reason 26 (<0.1%) 656 (1.7%) 
  Any diabetes-related reason 26 (<0.1%) 664 (1.7%) 
 Other medical   
  Pre-syncope/syncope 55 (0.2%) 261 (0.7%) 
  Palpitations 36 (<0.1%) 123 (0.3%) 
  Other cardiovascular 186 (0.5%) 436 (1.1%) 
  Respiratory 25 (<0.1%) 118 (0.3%) 
  Cancer 12 (<0.1%) 45 (0.1%) 
  Other 380 (1.1%) 1277 (3.3%) 
  Contraindicated medication 25 (<0.1%) 49 (0.1%) 
  Medical advice 90 (0.2%) 157 (0.4%) 
  Planned revascularization 8 (<0.1%) 45 (0.1%) 
  Any other medical reason 802 (2.2%) 2354 (6.1%) 
Any medical reason 2211 (6.1%) 9798 (25.5%) 
Non-medical reasons   
  Patient wishes/did not attend 1502 (4.2%) 2403 (6.3%) 
  Difficulty swallowing tablets 68 (0.2%) 746 (1.9%) 
  Other 639 (1.8%) 1317 (3.4%) 
Any non-medical reason 1988 (5.5%) 3804 (9.9%) 
Any reason 4055 (11.2%) 12 696 (33.1%) 

Participants may report more than one reason for withdrawal. Percentages are shown relative to the number of participants entering the phase. LDL-lowering therapy alone: LDL stabilization on simvastatin 40 mg or ezetimibe/simvastatin 10/40 mg daily. LDL-lowering therapy plus active ERN/L: LDL-lowering treatment plus ER niacin/laropiprant (1 g daily for 4 weeks increasing to 2 g daily for 4 weeks).

aIncludes routinely sought symptoms at run-in and randomization visits.

bMeasured at run-in and randomization visits: participants were excluded if >2× upper limit of normal.

Baseline characteristics of randomized participants

Between April 2007 and July 2010, a total of 25 673 people were randomized: 10 932 from China, 8035 from the UK, and 6706 from Scandinavia (see Table 2 and Supplementary material online, Table S1). There were a number of differences between the participants in China and Europe (e.g. those from China were more likely to have prior cerebrovascular disease or diabetes and to smoke, and less likely to drink alcohol or be on a statin prior to screening, although the use of non-study treatments was similar). Blood lipid levels on the background LDL-lowering therapy (prior to the start of the pre-randomization ERN/LRPT) are shown in Table 3 and Supplementary material online, Table S2. The mean total cholesterol was 3.32 (SD 0.57) mmol/L, LDL-C was 1.64 (0.44) mmol/L, HDL-C was 1.14 (0.29) mmol/L and triglycerides were 1.43 (0.84) mmol/L, with lower average values among the participants in China. Following the addition of run-in treatment with ERN/LRPT, there were reductions in LDL-C of 0.34 (SE 0.003) mmol/L, apoB of 0.10 (0.001) g/L, and triglycerides of 0.26 (0.004) mmol/L, and increases in HDL-C of 0.18 (0.001) mmol/L and apoA1 of 0.06 (0.001) g/L, with similar proportional changes in China and Europe.

Table 2

Selected baseline characteristics of randomized participants

 China Europe All 
Number randomized 10 932 14 741 25 673 
 Mean age (SD) 63.4 (7.6) 65.9 (7.2) 64.9 (7.5) 
 Male (%) 8680 (79.4%) 12 549 (85.1%) 21 229 (82.7%) 
History    
 Coronary disease 8407 (76.9%) 11 730 (79.6%) 20 137 (78.4%) 
 Cerebrovascular disease 4462 (40.8%) 3708 (25.2%) 8170 (31.8%) 
 Peripheral arterial disease 508 (4.6%) 2706 (18.4%) 3214 (12.5%) 
 Diabetes mellitusa 4611 (42.2%) 3688 (25.0%) 8299 (32.3%) 
 Treated hypertension 6894 (63.1%) 9025 (61.2%) 15 919 (62.0%) 
 Smoking status    
  Never 4197 (38.4%) 4529 (30.7%) 8726 (34.0%) 
  Former 4248 (38.9%) 8089 (54.9%) 12 337 (48.1%) 
  Current 2487 (22.7%) 2123 (14.4%) 4610 (18.0%) 
 Alcohol intake (units/week)    
  None 9516 (87.0%) 5669 (38.5%) 15 185 (59.1%) 
  >0 <21 1243 (11.4%) 7780 (52.8%) 9023 (35.1%) 
  ≥21 173 (1.6%) 1292 (8.8%) 1465 (5.7%) 
Physical measurements    
 Mean systolic blood pressure (mmHg) (SD) 142.8 (22.4) 144.1 (20.1) 143.5 (21.1) 
 Mean diastolic blood pressure (mmHg) (SD) 79.9 (12.2) 81.1 (10.7) 80.6 (11.4) 
 Mean body mass index (kg/m2) (SD) 26.2 (3.3) 28.8 (5.0) 27.7 (4.5) 
Medications    
 Current statin use (years)    
  None 5625 (51.5%) 566 (3.8%) 6191 (24.1%) 
  >0 <3 4339 (39.7%) 3811 (25.9%) 8150 (31.7%) 
  ≥3 968 (8.9%) 10 364 (70.3%) 11 332 (44.1%) 
 Study LDL-lowering therapy (daily)    
  Simvastatin 40 mg 8051 (73.6%) 5491 (37.2%) 13 542 (52.7%) 
  Ezetimibe/simvastatin 10/40 mg 2881 (26.4%) 9250 (62.8%) 12 131 (47.3%) 
 Non-study medications    
  Aspirin 9417 (86.1%) 12 742 (86.4%) 22 159 (86.3%) 
  Other antiplatelet 1910 (17.5%) 2727 (18.5%) 4637 (18.1%) 
  ACEi or ARBb 4657 (42.6%) 10 090 (68.4%) 14 747 (57.4%) 
  Diuretic 969 (8.9%) 3750 (25.4%) 4719 (18.4%) 
  Calcium channel blocker 3454 (31.6%) 3638 (24.7%) 7092 (27.6%) 
  Beta blocker 5635 (51.5%) 9495 (64.4%) 15 130 (58.9%) 
 China Europe All 
Number randomized 10 932 14 741 25 673 
 Mean age (SD) 63.4 (7.6) 65.9 (7.2) 64.9 (7.5) 
 Male (%) 8680 (79.4%) 12 549 (85.1%) 21 229 (82.7%) 
History    
 Coronary disease 8407 (76.9%) 11 730 (79.6%) 20 137 (78.4%) 
 Cerebrovascular disease 4462 (40.8%) 3708 (25.2%) 8170 (31.8%) 
 Peripheral arterial disease 508 (4.6%) 2706 (18.4%) 3214 (12.5%) 
 Diabetes mellitusa 4611 (42.2%) 3688 (25.0%) 8299 (32.3%) 
 Treated hypertension 6894 (63.1%) 9025 (61.2%) 15 919 (62.0%) 
 Smoking status    
  Never 4197 (38.4%) 4529 (30.7%) 8726 (34.0%) 
  Former 4248 (38.9%) 8089 (54.9%) 12 337 (48.1%) 
  Current 2487 (22.7%) 2123 (14.4%) 4610 (18.0%) 
 Alcohol intake (units/week)    
  None 9516 (87.0%) 5669 (38.5%) 15 185 (59.1%) 
  >0 <21 1243 (11.4%) 7780 (52.8%) 9023 (35.1%) 
  ≥21 173 (1.6%) 1292 (8.8%) 1465 (5.7%) 
Physical measurements    
 Mean systolic blood pressure (mmHg) (SD) 142.8 (22.4) 144.1 (20.1) 143.5 (21.1) 
 Mean diastolic blood pressure (mmHg) (SD) 79.9 (12.2) 81.1 (10.7) 80.6 (11.4) 
 Mean body mass index (kg/m2) (SD) 26.2 (3.3) 28.8 (5.0) 27.7 (4.5) 
Medications    
 Current statin use (years)    
  None 5625 (51.5%) 566 (3.8%) 6191 (24.1%) 
  >0 <3 4339 (39.7%) 3811 (25.9%) 8150 (31.7%) 
  ≥3 968 (8.9%) 10 364 (70.3%) 11 332 (44.1%) 
 Study LDL-lowering therapy (daily)    
  Simvastatin 40 mg 8051 (73.6%) 5491 (37.2%) 13 542 (52.7%) 
  Ezetimibe/simvastatin 10/40 mg 2881 (26.4%) 9250 (62.8%) 12 131 (47.3%) 
 Non-study medications    
  Aspirin 9417 (86.1%) 12 742 (86.4%) 22 159 (86.3%) 
  Other antiplatelet 1910 (17.5%) 2727 (18.5%) 4637 (18.1%) 
  ACEi or ARBb 4657 (42.6%) 10 090 (68.4%) 14 747 (57.4%) 
  Diuretic 969 (8.9%) 3750 (25.4%) 4719 (18.4%) 
  Calcium channel blocker 3454 (31.6%) 3638 (24.7%) 7092 (27.6%) 
  Beta blocker 5635 (51.5%) 9495 (64.4%) 15 130 (58.9%) 

aSelf-reported, or baseline plasma glucose ≥ 11.1 mmol/L if fasted <8 h or ≥7.0 mmol/L if fasted ≥8 h, or baseline HbA1c ≥48 mmol/mol, or use of hypoglycaemic medication at randomization.

bAngiotensin-converting enzyme inhibitor (ACEi) or angiotensin-2 receptor blocker (ARB).

Table 3

Effects (means and standard errors) of ER niacin/laropiprant on lipid measures after 8 week pre-randomization run-in

 China Europe All 
Total cholesterol 
 Baseline (mmol/L) 3.14 (0.005) 3.45 (0.005) 3.32 (0.004) 
 Absolute change (mmol/L) −0.23 (0.006) −0.18 (0.005) −0.20 (0.004) 
 Per cent change (%) −6.5 (0.19) −4.5 (0.15) −5.4 (0.12) 
LDL-C    
 Baseline (mmol/L) 1.51 (0.004) 1.74 (0.004) 1.64 (0.003) 
 Absolute change (mmol/L) −0.32 (0.005) −0.36 (0.004) −0.34 (0.003) 
 Per cent change (%) −20.1 (0.31) −19.8 (0.23) −19.9 (0.19) 
ApoB    
 Baseline (g/L) 0.65 (0.001) 0.70 (0.001) 0.68 (0.001) 
 Absolute change (g/L) −0.10 (0.001) −0.10 (0.001) −0.10 (0.001) 
 Per cent change (%) −13.8 (0.21) −13.2 (0.16) −13.5 (0.13) 
HDL-C    
 Baseline (mmol/L) 1.06 (0.002) 1.19 (0.003) 1.14 (0.002) 
 Absolute change (mmol/L) 0.15 (0.002) 0.20 (0.002) 0.18 (0.001) 
 Per cent change (%) 15.9 (0.20) 17.6 (0.14) 16.9 (0.12) 
ApoA1    
 Baseline (g/L) 1.38 (0.002) 1.51 (0.002) 1.45 (0.002) 
 Absolute change (g/L) 0.04 (0.002) 0.08 (0.001) 0.06 (0.001) 
 Per cent change (%) 3.8 (0.12) 5.6 (0.10) 4.8 (0.08) 
Triglycerides    
 Baseline (mmol/L) 1.40 (0.008) 1.46 (0.007) 1.43 (0.005) 
 Absolute change (mmol/L) −0.29 (0.007) −0.24 (0.006) −0.26 (0.004) 
 Per cent change (%) −14.4 (0.42) −10.2 (0.31) −12.0 (0.25) 
 Median per cent change (IQR)a −23.4 (44.54) −17.0 (40.68) −19.5 (42.47) 
 China Europe All 
Total cholesterol 
 Baseline (mmol/L) 3.14 (0.005) 3.45 (0.005) 3.32 (0.004) 
 Absolute change (mmol/L) −0.23 (0.006) −0.18 (0.005) −0.20 (0.004) 
 Per cent change (%) −6.5 (0.19) −4.5 (0.15) −5.4 (0.12) 
LDL-C    
 Baseline (mmol/L) 1.51 (0.004) 1.74 (0.004) 1.64 (0.003) 
 Absolute change (mmol/L) −0.32 (0.005) −0.36 (0.004) −0.34 (0.003) 
 Per cent change (%) −20.1 (0.31) −19.8 (0.23) −19.9 (0.19) 
ApoB    
 Baseline (g/L) 0.65 (0.001) 0.70 (0.001) 0.68 (0.001) 
 Absolute change (g/L) −0.10 (0.001) −0.10 (0.001) −0.10 (0.001) 
 Per cent change (%) −13.8 (0.21) −13.2 (0.16) −13.5 (0.13) 
HDL-C    
 Baseline (mmol/L) 1.06 (0.002) 1.19 (0.003) 1.14 (0.002) 
 Absolute change (mmol/L) 0.15 (0.002) 0.20 (0.002) 0.18 (0.001) 
 Per cent change (%) 15.9 (0.20) 17.6 (0.14) 16.9 (0.12) 
ApoA1    
 Baseline (g/L) 1.38 (0.002) 1.51 (0.002) 1.45 (0.002) 
 Absolute change (g/L) 0.04 (0.002) 0.08 (0.001) 0.06 (0.001) 
 Per cent change (%) 3.8 (0.12) 5.6 (0.10) 4.8 (0.08) 
Triglycerides    
 Baseline (mmol/L) 1.40 (0.008) 1.46 (0.007) 1.43 (0.005) 
 Absolute change (mmol/L) −0.29 (0.007) −0.24 (0.006) −0.26 (0.004) 
 Per cent change (%) −14.4 (0.42) −10.2 (0.31) −12.0 (0.25) 
 Median per cent change (IQR)a −23.4 (44.54) −17.0 (40.68) −19.5 (42.47) 

Changes are shown between measures taken at the baseline visit (after stabilization on LDL-lowering therapy alone) and the randomization visit (after 8 weeks of LDL-lowering plus active ER niacin/laropiprant 1 g daily for 4 weeks increasing to 2 g daily for 4 weeks). At the baseline visit 64.3% of participants reported fasting for >8 h. At the randomization visit 29.6% of participants reported fasting for >8 h.

aThe median per cent change and the interquartile range (IQR) are reported as the per cent change in triglycerides is highly skewed.

Compliance with background LDL-lowering therapy

The present analyses are based on follow-up to the scheduled end of the study treatment period, by which time there was median follow-up of 3.9 years (mean 3.6 years). The proportion of participants reporting taking at least 80% of their study LDL-lowering treatment was 92, 89, and 85% after 1, 2, and 3 years follow-up respectively. The proportion who stopped was slightly higher among participants allocated ERN/LRPT than those allocated placebo (13.7% vs. 11.7%, P < 0.0001). Participants who stopped study LDL-lowering therapy were advised to discuss the use of non-study statins with their own doctors (18% of the participants in China who had stopped started non-study statin compared with 73% of the participants in Europe).

Safety and tolerability of ER niacin/laropiprant

By 3.9 years of follow-up, 25.4% of the participants allocated active ERN/LRPT had stopped their randomized treatment compared with 16.6% of those on placebo (Table 4). Most of this excess was attributed to medical reasons (16.4% vs. 7.9%), chiefly skin and gastrointestinal reasons, with some differences in the patterns seen in China and Europe (Supplementary material online, Table S3).

Table 4

Reasons for stopping randomized treatment during follow-up

 ERN/LRPT Placebo Excessa (SE) P
Number randomized 12 838 12 835   
 Total not continuing randomized treatment 3256 (25.4%) 2136 (16.6%) 8.7% (0.5%) <0.0001 
Medical reasons 
 Skin     
  Pruritis 432 90   
  Rash 132 47   
  Flushing 106 14   
  Other skin 27   
  Any skin reason 697 (5.4%) 160 (1.2%) 4.2% (0.2%) <0.0001 
 Gastrointestinal (GI) 
  Any upper GI 227 104   
  Any lower GI 205 73   
  Other GI 63 42   
  Any GI reason 495 (3.9%) 219 (1.7%) 2.1% (0.2%) <0.0001 
 Hepatobiliary 
  Abnormal alanine transaminase 38 30   
  Other hepatobiliary 14 13   
  Any hepatobiliary reason 52 (0.4%) 43 (0.3%) 0.1% (0.1%) 0.36 
 Musculoskeletal 
  Muscle symptoms 151 90   
  Rheumatological 18 21   
  Gout 26   
  Abnormal creatine kinase 25   
  Other musculoskeletal   
  Any musculoskeletal reason 225 (1.8%) 128 (1.0%) 0.8% (0.1%) <0.0001 
 Diabetes 
  New-onset diabetes mellitus 13   
  Major diabetes complication   
  Other diabetes-related reason 104 45   
  Any diabetes-related reason 119 (0.9%) 50 (0.4%) 0.5% (0.1%) <0.0001 
 Other medical 
  Pre-syncope/syncope 23 16   
  Palpitations   
  Other cardiovascular 75 80   
  Respiratory 20 13   
  Cancer 65 62   
  Other 185 150   
  Contraindicated medication   
  Medical advice 135 94   
  Any other medical reason 520 (4.1%) 421 (3.3%) 0.8% (0.2%) 0.001 
  Any medical reason 2107 (16.4%) 1020 (7.9%) 8.5% (0.4%) <0.0001 
Non-medical reasons 
 Patient wishes 626 580   
 Difficulty swallowing tablets 258 361   
 Other 265 175   
Any non-medical reason 1149 (8.9%) 1116 (8.7%) 0.3% (0.4%) 0.47 
Any reason for stopping 3256 (25.4%) 2136 (16.6%) 8.7% (0.5%) <0.0001 
 ERN/LRPT Placebo Excessa (SE) P
Number randomized 12 838 12 835   
 Total not continuing randomized treatment 3256 (25.4%) 2136 (16.6%) 8.7% (0.5%) <0.0001 
Medical reasons 
 Skin     
  Pruritis 432 90   
  Rash 132 47   
  Flushing 106 14   
  Other skin 27   
  Any skin reason 697 (5.4%) 160 (1.2%) 4.2% (0.2%) <0.0001 
 Gastrointestinal (GI) 
  Any upper GI 227 104   
  Any lower GI 205 73   
  Other GI 63 42   
  Any GI reason 495 (3.9%) 219 (1.7%) 2.1% (0.2%) <0.0001 
 Hepatobiliary 
  Abnormal alanine transaminase 38 30   
  Other hepatobiliary 14 13   
  Any hepatobiliary reason 52 (0.4%) 43 (0.3%) 0.1% (0.1%) 0.36 
 Musculoskeletal 
  Muscle symptoms 151 90   
  Rheumatological 18 21   
  Gout 26   
  Abnormal creatine kinase 25   
  Other musculoskeletal   
  Any musculoskeletal reason 225 (1.8%) 128 (1.0%) 0.8% (0.1%) <0.0001 
 Diabetes 
  New-onset diabetes mellitus 13   
  Major diabetes complication   
  Other diabetes-related reason 104 45   
  Any diabetes-related reason 119 (0.9%) 50 (0.4%) 0.5% (0.1%) <0.0001 
 Other medical 
  Pre-syncope/syncope 23 16   
  Palpitations   
  Other cardiovascular 75 80   
  Respiratory 20 13   
  Cancer 65 62   
  Other 185 150   
  Contraindicated medication   
  Medical advice 135 94   
  Any other medical reason 520 (4.1%) 421 (3.3%) 0.8% (0.2%) 0.001 
  Any medical reason 2107 (16.4%) 1020 (7.9%) 8.5% (0.4%) <0.0001 
Non-medical reasons 
 Patient wishes 626 580   
 Difficulty swallowing tablets 258 361   
 Other 265 175   
Any non-medical reason 1149 (8.9%) 1116 (8.7%) 0.3% (0.4%) 0.47 
Any reason for stopping 3256 (25.4%) 2136 (16.6%) 8.7% (0.5%) <0.0001 

aExcess is defined as the absolute percentage of patients who had the event in the ERN/LRPT group minus the percentage who had the event in the placebo group.

*P-values are calculated from z tests comparing the proportion of patients who had the event in the ERN/LRPT group with the proportion of patients who had the event in the placebo group.

Skin

Skin-related reasons for stopping the randomized treatment were about four times more common among participants allocated ERN/LRPT (5.4% vs. 1.2%: Table 4), with a bigger excess among participants in Europe. Most of this excess was due to pruritis (3.4% vs. 0.7%), with the remainder attributed to rash (1.0% vs. 0.4%) and flushing (0.8% vs. 0.1%). Most of the rashes were maculopapular (although blistering occurred in a few participants), typically resolving within a few days of stopping study treatment (although occasionally taking several weeks), and with only 14 cases resulting in hospitalization.

Gastrointestinal and hepatobiliary

Gastrointestinal reasons for stopping the randomized treatment were about twice as common among participants allocated ERN/LRPT (3.9% vs. 1.7%: Table 4). Most of this excess was attributed to indigestion and diarrhoea, which did not usually result in hospital admission. There was no difference between the treatment groups in the numbers of participants who stopped for any hepatobiliary reasons, but allocation to ERN/LRPT approximately doubled the incidence of raised transaminases detected at routine follow-up visits (Table 5): ALT >3× ULN in 0.30%/year vs. 0.14%/year. Consecutive ALT >3× ULN within 2–7 days were seen in 0.19%/year vs. 0.07%/year. This excess of raised ALT was seen chiefly among the participants in China: for example, excess of consecutive ALT >3× ULN of 0.24%/year compared with 0.02%/year in Europe; Supplementary material online, Tables S4 and S5). Furthermore, this excess was markedly attenuated after exclusion of participants with muscle damage (which can elevate ALT levels): for example, excess of consecutive ALT >3× ULN in the absence of detected muscle damage of 0.07%/year in China vs. 0.02% in Europe. The more serious hepatobiliary combination of ALT >3× ULN plus bilirubin ≥2× ULN was similar in the two treatment groups either when detected routinely or from all results, with similar rates in China and Europe. There were 36 cases of hepatitis recorded (27 in China; 9 in Europe), of which 20 were attributed to viral and 16 to non-viral causes; only 6 of the non-viral cases (4 in China; 2 in Europe) had no alternative cause identified, 4 (0.01%) allocated ERN/LRPT vs. 2 (0.005%) allocated placebo. All six cases had ALT >10× ULN and four (2 vs. 2) also had bilirubin ≥2× ULN; all were receiving randomized treatment at the time of the event and all of them recovered. Only one man, who was found to have underlying chronic liver disease, was significantly unwell and developed a coagulopathy (but not encephalopathy).

Table 5

Liver- and muscle-related events (per cent per year) during follow-up

 ERN/LRPT Placebo P
Number randomized 12 838 12 835  
Person years follow-up 46 239 46 359  
Abnormal alanine transaminase 
 Results collected at routine visits    
  >3 ≤5× ULN 111 (0.24) 47 (0.10)  
  >5 ≤10× ULN 23 (0.05) 15 (0.03)  
  >10× ULN 6 (0.01) 5 (0.01)  
  Any >3× ULN 140 (0.30) 67 (0.14) <0.0001 
  Any >3× ULN without muscle damagea 124 (0.27) 65 (0.14) <0.0001 
  >3× ULN + bilirubin ≥2× ULN 3 (<0.01) 5 (0.01) 0.72 
 All resultsb    
  >3 ≤5× ULN 190 (0.41) 76 (0.16)  
  >5 ≤10× ULN 81 (0.18) 35 (0.08)  
  >10× ULN 44 (0.10) 22 (0.05)  
  Any >3× ULN 315 (0.68) 133 (0.29) <0.0001 
  Any >3× ULN without muscle damagea 234 (0.51) 119 (0.26) <0.0001 
  Consecutive >3× ULN 88 (0.19) 34 (0.07) <0.0001 
  Consecutive >3× ULN without muscle damagea 48 (0.10) 30 (0.06) 0.04 
  >3× ULN + bilirubin ≥2× ULN 14 (0.03) 18 (0.04) 0.48 
Myopathy 
 Definite myopathy    
  Rhabdomyolysis 7 (0.02) 5 (0.01)  
 Any definite myopathy 75 (0.16) 17 (0.04) <0.0001 
 Incipient myopathyc    
  Symptomatic 23 (0.05) 12 (0.03)  
  Asymptomatic 59 (0.13) 10 (0.02)  
 Any incipient myopathy 81 (0.18) 21 (0.05) <0.0001 
 Any myopathyd 155 (0.34) 38 (0.08) <0.0001 
 ERN/LRPT Placebo P
Number randomized 12 838 12 835  
Person years follow-up 46 239 46 359  
Abnormal alanine transaminase 
 Results collected at routine visits    
  >3 ≤5× ULN 111 (0.24) 47 (0.10)  
  >5 ≤10× ULN 23 (0.05) 15 (0.03)  
  >10× ULN 6 (0.01) 5 (0.01)  
  Any >3× ULN 140 (0.30) 67 (0.14) <0.0001 
  Any >3× ULN without muscle damagea 124 (0.27) 65 (0.14) <0.0001 
  >3× ULN + bilirubin ≥2× ULN 3 (<0.01) 5 (0.01) 0.72 
 All resultsb    
  >3 ≤5× ULN 190 (0.41) 76 (0.16)  
  >5 ≤10× ULN 81 (0.18) 35 (0.08)  
  >10× ULN 44 (0.10) 22 (0.05)  
  Any >3× ULN 315 (0.68) 133 (0.29) <0.0001 
  Any >3× ULN without muscle damagea 234 (0.51) 119 (0.26) <0.0001 
  Consecutive >3× ULN 88 (0.19) 34 (0.07) <0.0001 
  Consecutive >3× ULN without muscle damagea 48 (0.10) 30 (0.06) 0.04 
  >3× ULN + bilirubin ≥2× ULN 14 (0.03) 18 (0.04) 0.48 
Myopathy 
 Definite myopathy    
  Rhabdomyolysis 7 (0.02) 5 (0.01)  
 Any definite myopathy 75 (0.16) 17 (0.04) <0.0001 
 Incipient myopathyc    
  Symptomatic 23 (0.05) 12 (0.03)  
  Asymptomatic 59 (0.13) 10 (0.02)  
 Any incipient myopathy 81 (0.18) 21 (0.05) <0.0001 
 Any myopathyd 155 (0.34) 38 (0.08) <0.0001 

aMuscle damage defined as simultaneous creatine kinase >5× baseline and >3× ULN (within 7 days) of the ALT abnormality or diagnosis of myopathy (within 28 days).

bIncludes results collected at routine and recall visits as well as external reports.

cIncipient myopathy with no definite myopathy within 28 days.

dOf these individuals 180/193 were taking randomized treatment and 191/193 were taking study or non-study LDL-lowering treatment at the time of their first myopathy event.

*P-values are calculated from z tests comparing the proportion of patients who had the event in the ERN/LRPT group with the proportion of patients who had the event in the placebo group.

Diabetes

Diabetic complications (typically hyperglycaemia) were about twice as common as a reason for stopping randomized treatment in participants allocated ERN/LRPT (0.9% vs. 0.4%: Table 4). More of these events led to hospitalization in China than in Europe, perhaps indicating a different threshold for hospitalization in the different regions. Participants who developed diabetes mellitus were encouraged to continue their study treatment and this was rarely given as a reason for stopping.

Muscle

Overall, musculoskeletal symptoms were only slightly more commonly given as a reason for stopping study treatment among participants allocated ERN/LRPT (1.8% vs. 1.0%: Table 4). However, compared with the placebo group, the risk ratio for definite myopathy with ERN/LRPT was 4.4 (95% CI 2.6–7.5; P < 0.0001; 0.16%/year vs. 0.04%/year: Table 5); all of these patients had both their study LDL-lowering and randomized treatments stopped. The excess risk was greater in the first year (0.29%/year vs. 0.04%/year) than in subsequent years (0.11%/year vs. 0.04%/year). In addition, the risk ratio for incipient myopathy was 3.9 (95% CI 2.4–6.3; P < 0.0001; 0.18%/year vs. 0.05%/year); these patients were typically advised to stop their randomized treatments and only one went on to develop definite myopathy. Overall, the risk ratio for any (definite or incipient) myopathy was 4.1 (95% CI 2.9–5.9; P < 0.0001). (Restricting this analysis to the 180 participants who were receiving randomized treatment at the time of the myopathy did not alter the results materially.) Most of these cases had relatively mild symptoms and were managed as outpatients, but rhabdomyolysis—which always required hospitalization—occurred in 7 (0.02%/year) participants allocated active ERN/LRPT vs. 5 (0.01%/year) allocated placebo (RR 1.4; 95% CI 0.4–4.4; P= 0.56). One of these cases was significantly unwell: she developed rhabdomyolysis following admission for diabetic ketoacidosis and then had a fatal haemorrhagic stroke. In addition, one participant admitted with a stroke which was complicated by an MI developed myopathy and died shortly afterwards.

The absolute risk of any myopathy (definite or incipient) among participants allocated study LDL-lowering therapy alone (i.e. the placebo group for the randomized comparison) was much higher in China than in Europe (0.13%/year vs. 0.04%/year; P = 0.001; Supplementary material online, Tables S4 and S5). In addition, the relative excess with allocation to ERN/LRPT was greater in China (RR 5.2; 95% CI 3.4–7.8) than in Europe (RR 1.5; 95% CI 0.7–3.3), and these risk ratios were significantly different from each other (interaction P-value = 0.008). As a consequence, the absolute excess of any myopathy associated with adding ERN/LRPT to statin-based LDL-lowering therapy was over 10 times greater among participants in China than among those in Europe (0.53%/year vs. 0.03%/year).

Discussion

HPS2-THRIVE is the largest ever randomized trial of ER niacin treatment and the present report provides uniquely reliable information about its tolerability and side-effect profile. About one-third of the potentially eligible individuals who started the 2-month ERN/LRPT run-in phase were excluded prior to randomization, with many reporting known side effects of niacin. Consequently, HPS2-THRIVE is assessing the clinical efficacy and safety of ERN/LRPT among the types of patient at high risk of vascular events who are likely to be able to take it long term, which is the relevant question in clinical practice.

Known side effects of niacin on the skin, gastrointestinal system and diabetes account for most of the excess of medical reasons given for stopping ERN/LRPT during both the pre-randomization run-in and post-randomization follow-up phases. Skin side effects account for about half the excess, with itching, rashes, and flushing all reported more frequently. Flushing has been a major cause of niacin intolerance18 but was less frequently reported than itching or rash in HPS2-THRIVE, perhaps due to laropiprant blocking prostaglandin D2 signalling (whereas itching and rash are mediated by prostaglandin E19). ERN/LRPT was also associated with an excess of indigestion and diarrhoea, but there was no apparent excess of hepatobiliary side effects.

A meta-analysis of niacin trials (predominantly among Caucasians not on a statin) did not find any evidence of an excess of muscle problems,12 and niacin is not thought to cause myopathy in the absence of statin therapy.20 However, during development of lovastatin, it was noted that the frequency of myopathy rose from 0.2% with lovastatin alone to 2% when co-administered with niacin.21 An important finding from the present analyses in HPS2-THRIVE is the highly significant four-fold excess risk of any myopathy with the addition of ERN/LRPT to simvastatin 40 mg daily (with or without ezetimibe 10 mg daily). This excess risk was particularly marked among the participants in China, where the background rate of myopathy with the study LDL-lowering therapy alone was higher than among the participants in Europe. During 2009, after definite myopathy had been recorded in 52 (including 34 after randomization) participants in China (and only 4 in Europe), the independent Data Monitoring Committee advised the investigators that it was substantially more frequent in the participants allocated active ERN/LRPT and the prescribing information was updated accordingly.22,23

The mechanism for this myopathy-related interaction between niacin and simvastatin is not clear. Nor is it clear why the rate of myopathy on simvastatin alone is higher among Chinese individuals. Niacin does not inhibit cytochrome P450 3A4 or interfere with statin-glucuronidation, but it has been found to increase simvastatin blood concentrations by about one-third,24 and statin-induced myopathy is known to be associated with higher blood statin levels.25 Asian subjects are also recognized to have higher blood levels than Caucasians following a given statin dose and this too may be a contributory factor.26 However, it should be noted that—even among Chinese individuals—this small absolute excess of myopathy with simvastatin 40 mg daily (with or without niacin) is likely to be greatly outweighed by its cardiovascular benefits in the sort of high-risk patients included in HPS2-THRIVE.1

Niacin has a variety of effects on lipids, including lowering LDL-C, apoB, and Lp(a) and raising HDL-C and apoA1, which might be expected to translate into reductions in vascular events. Over 25 000 people at high risk of vascular events were randomized in HPS2-THRIVE and three-quarters remained compliant with ERN/LRPT after 3.9 years' median follow-up. Based on this compliance and the lipid changes observed during the pre-randomization run-in, it was estimated prior to unblinding the trial that study average differences in LDL-C of ∼0.25 mmol/L and HDL-C of ∼0.13 mmol/L would have been achieved. Based on previous observational studies and randomized trials,1 it was anticipated that such lipid differences might translate into a 10–15% reduction in vascular events. At least 3400 of these high-risk participants were expected to have confirmed MVEs during an average of ∼4 years of follow-up, so HPS2-THRIVE has excellent statistical power to detect or exclude effects of this magnitude.

Supplementary material

Supplementary material is available at European Heart Journal online.

Funding

HPS2-THRIVE was funded by a grant to Oxford University from Merck (manufacturers of ER niacin/laropiprant, ezetimibe and simvastatin), but the study was designed, and has been conducted, analysed and interpreted, independently by the Clinical Trial Service Unit & Epidemiological Studies Unit (CTSU) at the University of Oxford which is the regulatory sponsor for the trial. CTSU receives funding from the UK Medical Research Council, the British Heart Foundation and Cancer Research UK. J.C.H. acknowledges support from the BHF Centre of Research Excellence, Oxford (RE/08/004).

Conflict of interest: The Clinical Trial Service Unit has a staff policy of not accepting honoraria or other payments from the pharmaceutical industry, except for the reimbursement of costs to participate in scientific meetings. L.J. and J.L. have no conflicts of interest to declare.

Acknowledgements

The most important acknowledgement is to the participants in the study and to the collaborators listed in the appendix.

Appendix

Writing Committee: Richard Haynesa, Lixin Jianga, Jemma C Hopewell, Jing Li, Fang Chen, Sarah Parish, Martin J. Landray, Rory Collinsb and Jane Armitageb (ajoint first authors; bjoint senior authors).

Steering Committee: R. Collins (Chairman). Principal investigators: J. Armitage (Clinical Coordinator), C. Baigent, Z. Chen and M. Landray. Regional coordinators: Y. Chen and L. Jiang (China), T. Pedersen (Scandinavia), and M. Landray (UK). Other members: L. Bowman, F. Chen, M. Hill, R. Haynes, C. Knott, K. Rahimi, J. Tobert and P. Sleight. Lay member: D. Simpson. Statistician: S. Parish. Computing: A. Baxter and M. Lay. Administrative coordinators: C. Bray, E. Wincott. Merck representatives (non-voting): G. Leijenhorst (formerly A. Skattebol and G. Moen), Y. Mitchel and O. Kuznetsova.

Data Monitoring Committee: S. MacMahon (Chairman), J. Kjekshus, C. Hill, T.H. Lam and P. Sandercock. Statisticians (non-voting): R. Peto and J.C. Hopewell.

References

1
Cholesterol Treatment Trialists' (CTT) Collaborators
Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials
Lancet
 , 
2010
, vol. 
376
 (pg. 
1670
-
1681
)
2
Perk
J
De Backer
G
Gohlke
H
Graham
I
Reiner
Z
Verschuren
M
Albus
C
Benlian
P
Boysen
G
Cifkova
R
Deaton
C
Ebrahim
S
Fisher
M
Germano
G
Hobbs
R
Hoes
A
Karadeniz
S
Mezzani
A
Prescott
E
Ryden
L
Scherer
M
Syvanne
M
Scholte op Reimer
WJ
Vrints
C
Wood
D
Zamorano
JL
Zannad
F
European Guidelines on cardiovascular disease prevention in clinical practice (version 2012). The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts). Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR)
Eur Heart J
 , 
2012
, vol. 
33
 (pg. 
1635
-
1701
)
3
Di Angelantonio
E
Sarwar
N
Perry
P
Kaptoge
S
Ray
KK
Thompson
A
Wood
AM
Lewington
S
Sattar
N
Packard
CJ
Collins
R
Thompson
SG
Danesh
J
Major lipids, apolipoproteins, and risk of vascular disease
JAMA
 , 
2009
, vol. 
302
 (pg. 
1993
-
2000
)
4
Bennet
A
Di Angelantonio
E
Erqou
S
Eiriksdottir
G
Sigurdsson
G
Woodward
M
Rumley
A
Lowe
GDO
Danesh
J
Gudnason
V
lipoprotein(a) levels and risk of future coronary heart disease: large-scale prospective data
Arch Intern Med
 , 
2008
, vol. 
168
 (pg. 
598
-
608
)
5
Carlson
LA
Nicotinic acid: the broad-spectrum lipid drug. A 50th anniversary review
J Intern Med
 , 
2005
, vol. 
258
 (pg. 
94
-
114
)
6
Maccubbin
D
Bays
HE
Olsson
AG
Elinoff
V
Elis
A
Mitchel
Y
Sirah
W
Betteridge
A
Reyes
R
Yu
Q
Kuznetsova
O
McCrary Sisk
C
Pasternak
RC
Paolini
JF
Lipid-modifying efficacy and tolerability of extended-release niacin/laropiprant in patients with primary hypercholesterolaemia or mixed dyslipidaemia
Int J Clin Practice
 , 
2008
, vol. 
62
 (pg. 
1959
-
1970
)
7
Clarke
R
Peden
JF
Hopewell
JC
Kyriakou
T
Goel
A
Heath
SC
Parish
S
Barlera
S
Franzosi
MG
Rust
S
Bennett
D
Silveira
A
Malarstig
A
Green
FR
Lathrop
M
Gigante
B
Leander
K
de Faire
U
Seedorf
U
Hamsten
A
Collins
R
Watkins
H
Farrall
M
Genetic variants associated with Lp(a) lipoprotein level and coronary disease
N Engl J Med
 , 
2009
, vol. 
361
 (pg. 
2518
-
2528
)
8
Bays
HE
Maccubbin
D
Meehan
AG
Kuznetsova
O
Mitchel
YB
Paolini
JF
Blood pressure-lowering effects of extended-release niacin alone and extended-release niacin/laropiprant combination: a post hoc analysis of a 24-week, placebo-controlled trial in dyslipidemic patients
Clin Ther
 , 
2009
, vol. 
31
 (pg. 
115
-
122
)
9
Grundy
SM
Vega
GL
McGovern
ME
Tulloch
BR
Kendall
DM
Fitz-Patrick
D
Ganda
OP
Rosenson
RS
Buse
JB
Robertson
DD
Sheehan
JP
Efficacy, safety, and tolerability of once-daily niacin for the treatment of dyslipidemia associated with type 2 diabetes: results of the assessment of diabetes control and evaluation of the efficacy of niaspan trial
Arch Intern Med
 , 
2002
, vol. 
162
 (pg. 
1568
-
1576
)
10
The Coronary Drug Project Research Group.
Clofibrate and niacin in coronary heart disease
JAMA
 , 
1975
, vol. 
231
 (pg. 
360
-
381
)
11
Boden
WE
Probstfield
JL
Anderson
T
Chaitman
BR
Desvignes-Nickens
P
Koprowicz
K
McBride
R
Teo
K
Weintraub
W
The AIM-HIGH Investigators
Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy
N Engl J Med
 , 
2011
, vol. 
365
 (pg. 
2255
-
2267
)
12
Birjmohun
RS
Hutten
BA
Kastelein
JJ
Stroes
ES
Efficacy and safety of high-density lipoprotein cholesterol-increasing compounds: a meta-analysis of randomized controlled trials
J Am Coll Cardiol
 , 
2005
, vol. 
45
 (pg. 
185
-
197
)
13
Maciejewski-Lenoir
D
Richman
JG
Hakak
Y
Gaidarov
I
Behan
DP
Connolly
DT
Langerhans cells release prostaglandin D2 in response to nicotinic acid
J Invest Dermatol
 , 
2006
, vol. 
126
 (pg. 
2637
-
2646
)
14
Lai
E
De Lepeleire
I
Crumley
TM
Liu
F
Wenning
LA
Michiels
N
Vets
E
O'Neill
G
Wagner
JA
Gottesdiener
K
Suppression of niacin-induced vasodilation with an antagonist to prostaglandin D2 receptor subtype 1
Clin Pharmacol Ther
 , 
2007
, vol. 
81
 (pg. 
849
-
857
)
15
SEARCH Collaborative Group
SLCO1B1 variants and statin-induced myopathy–a genomewide study
N Engl J Med
 , 
2008
, vol. 
359
 (pg. 
789
-
799
)
16
Lang
JM
Buring
JE
Rosner
B
Cook
N
Hennekens
CH
Estimating the effect of the run-in on the power of the Physicians' Health Study
Stat Med
 , 
1991
, vol. 
10
 (pg. 
1585
-
1593
)
17
White
SJ
Freedman
LS
Allocation of patients to treatment groups in a controlled clinical study
Br J Cancer
 , 
1978
, vol. 
37
 (pg. 
849
-
857
)
19
Hanson
J
Gille
A
Zwykiel
S
Lukasova
M
Clausen
BE
Ahmed
K
Tunaru
S
Wirth
A
Offermanns
S
Nicotinic acid- and monomethyl fumarate-induced flushing involves GPR109A expressed by keratinocytes and COX-2-dependent prostanoid formation in mice
J Clin Invest
 , 
2010
, vol. 
120
 (pg. 
2910
-
2919
)
20
Guyton
JR
Bays
HE
Safety considerations with niacin therapy
Am J Cardiol
 , 
2007
, vol. 
99
 (pg. 
S22
-
S31
)
21
Tobert
JA
Efficacy and long-term adverse effect pattern of lovastatin
Am J Cardiol
 , 
1988
, vol. 
62
 (pg. 
28J
-
34J
)
22
ZOCOR (simvastatin) tablets prescribing information
 
23
Tredapative 1000 mg/20 mg modified release tablets SPC
 
24
Kosoglou
T
Zhu
Y
Statkevich
P
Triantafyllou
I
Taggart
W
Xuan
F
Kim
KT
Cutler
DL
Assessment of potential pharmacokinetic interactions of ezetimibe/simvastatin and extended-release niacin tablets in healthy subjects
Eur J Clin Pharmacol
 , 
2011
, vol. 
67
 (pg. 
483
-
492
)
25
Armitage
J
The safety of statins in clinical practice
Lancet
 , 
2007
, vol. 
370
 (pg. 
1781
-
1790
)
26
Lee
E
Ryan
S
Birmingham
B
Zalikowski
J
March
R
Ambrose
H
Moore
R
Lee
C
Chen
Y
Schneck
D
Rosuvastatin pharmacokinetics and pharmacogenetics in white and Asian subjects residing in the same environment
Clin Pharmacol Ther
 , 
2005
, vol. 
78
 (pg. 
330
-
341
)

Author notes

The collaborators are listed in the appendix.
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by-nc/3.0/), which permits non-commercial reuse, distribution, and reproduction in any medium, provided that the original authorship is properly and fully attributed; the Journal, Learned Society and Oxford University Press are attributed as the original place of publication with correct citation details given; if an article is subsequently reproduced or disseminated not in its entirety but only in part or as a derivative work this must be clearly indicated. For commercial re-use, please contact journals.permissions@oup.com.

Comments

0 Comments